20170913 Immunicum Company Presentationimmunicum.se/wp-content/uploads/2017/09/20170913... · that suppress the immune system’s ability to kill cancer cells through checkpoint

CompanyPresentation

CarlosdeSousa,CEOSeptember2017

22

DisclaimerThis presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical

facts, contained in this presentation, including statements regarding Immunicum’s view on strategy, future operations, future clinical development plans and

objectives, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The

words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “target”, “potential”, “will”, “would” “can”, “could”, “shall”,

“should”, “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such

identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place

undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the

forward-looking statements we make. The forward-looking statements contained in this presentation reflect Immunicum’s current views with respect to

future events, and Immunicum assumes no obligation to update any forward-looking statements except as required by applicable law. Our actual results

and/or actual events could differ materially from those anticipated in forward-looking statements for many reasons, including, without limitation, risks

associated with our clinical development activities, chemistry, manufacturing and controls, regulatory oversight, product commercialization, upholding of

intellectual property rights or intellectual property claims, general market developments and other risks, uncertainties and factors within and outside of our

control. Given these risks, uncertainties and other factors, you should not place undue reliance on forward-looking statements, and we assume no obligation

to update forward-looking statements, even if new information becomes available in the future, or to provide information regarding the reasons why actual

outcome, events or results could differ materially from those anticipated in the forward-looking statements, except as required by law. You should instead

make or, if you are not qualified to do so, seek the assistance of qualified and professional counsel in making, an independent and adequately substantiated

assessment of us, our operations, current and future activities and commercial potential based on all available information about us, as presented in financial

reports, press releases and in other contexts, and about the business fields and markets in which we are active, as presented in, inter alia, scientific and other

publications (although we do not assume any responsibility for information about us obtained from third parties).

2

1

2

3

4

5

6

Tableofcontents

IntroductiontoImmunicumUniqueimmuno-oncologyapproachofallogeneic,off-the-shelfcell-basedtherapies

IlixadencelApotentialbackbonetherapyinfutureoncologytoolkitofcombinationtherapies

UpdatedclinicaldevelopmentplanAcceleratingvaluecreationandestablishingilixadencel aspartofstandardofcare

ManagementandboardExperiencedmanagementteamwithextensiveexperienceindrugandbusinessdevelopment

Financials

Appendix

44

FirstpatientenrolledinRCCPhaseIIstudy(MERECA)

ClinicalPhaseI/IIstudyinitiated(HCC)

ClinicalPhaseI/IIstudyfortreatmentoflivercancer(HCC)isinitiated

PatentforCOMBIGgrantedintheUS

TheUSPatentandTrademarkOfficegrantspatentfortheCOMBIGplatform

Companyhistory

2011 2012 2015

2013 2014 2016

2017

2002

Companyfounded

Spin-off

NewdevelopmentplanLaunchofthenewclinicaldevelopment

plan

FirstpatientenrolledinPhaseI/IItrial(GIST)

Thestudyinvestigatesthesafetyandefficacyofilixadencel incombination

withTKIs

SEK128mraisedArightsissuetopartiallyfinanceongoingandplannedstudies(RCC,HCCandGIST)

NewCEOappointedCarlosdeSousaisappointedCEOtotake

thecompanytothenextstageofdevelopment

ClinicalPhaseI/IIstudyinitiated(RCC)

ClinicalPhaseI/IIstudyfortreatmentofkidneycancer(RCC)isinitiated

ShareslistedonNasdaqFirstNorth

FinalreportforPhaseI/IItrial(RCC)submitted

FinalreportwassubmittedtoSwedishMPA.Noseriousadverseeventswere

noted

PatentfortheCOMBIGplatformgranted

TheEuropeanPatentOffice(EPO)grantspatentprotectionfortheCOMBIG

platform

PublicationofresultsPhaseI/IItrialofilixadencel inRCCResultspublishedintheJournalofImmuno

TherapyofCancer

FirstclinicaltrialapprovedSwedishMPAapprovesclinicaltrialofINTUVAX(ilixadencel)fortreatmentof

kidneycancer

INDapprovalinUSFDAclearedINDforilixadencel tostart

treatingpatientsinUS

ExpectedlistingonNasdaqStockholm

55

Immuno-oncologyisthefastestgrowingpharmaceuticalsegment

Immuno-Oncology isdesignedtohelpthebody'sownimmunesystemfightcancer

byeitheractivating theimmunesystemagainstcancercellsorbyinhibitingfactors

thatsuppresstheimmunesystem’sabilitytokillcancercellsthroughcheckpoint

inhibitors.

I MM U N O - O N C O L O G Y I N B R I E F

$17bnT O T A L M A R K E T S I Z E 2 0 1 5 1

$76bnT O T A L M A R K E T S I Z E 2 0 2 2 1

24%C A G R 2 0 1 5 - 2 0 2 2 1

F D A A P P R O V E D C H E C K P O I N T I N H I B I T O R S

2 0 1 1 2 0 1 4 2 0 1 4

2 0 1 6 2 0 1 7 2 0 1 7

Theimmuno-oncologymarketwasfirstopenedbycheckpointinhibitorsthattargetthetumor’simmunosuppression

Source:(1)RadiantInsights- GlobalCancerImmunotherapiesMarketto2022,2016.

66

Inhibitionofthetumor’simmunosuppressionisnotenough

Combinationtherapiesofimmunesystemactivatorsandimmunosuppressioninhibitorscouldenablethenextbreakthrough

Sources:Immuno-oncologycombinations:raisingthetailofthesurvivalcurve;Harrisetal.,CancerBiolMed.2016;Immunotherapy:RevolutionizingCancerTreatmentWebinar,FocusedUltrasoundFoundation;Bristol-MyersSquibb,InvestorPresentation(March31,2016);CombinationImmunotherapyforLungCancer:TheWaveofthefuture,TheASCOPost;CombinationTherapies:WhatWorksBestforImmuno-Oncology,TheAmericanJournalofManagedCare

Immunotherapycombination

Immunotherapymonotherapy

Traditionaltherapies

Control

TIMEFROMTREATMENT

PROPO

RTIONALIVE

Theimmunesystemalsoneedstobeactivatedtorecognizeandfindcancercells

Thefield[immuno-oncology]ismovingtowards

personalized,combinationalimmunotherapy.

- JillO’Donnel-Tormey,CEOoftheCancerResearch

Institute

” ”Combinationsarethefuture[…]Theyear2017willbe

animportantoneasweseesomeofthecombination

Immunotherapydatareadingout.

- NaiyerRizvi,MD,DirectorofImmunotherapeuticsat

ColumbiaUniversityMedicalCenter

””

Thefutureofthesedrugsisincombination

strategies[…]And,mostofthedatathatareleaking

outofASCOandothermeetingsarelookingat

combinations.

- BenjaminP.Levy,ClinicalDirectorofMedical

OncologyatKimmelCancerCentre

””

77

Killingofcancercells7

6 RecognitionofcancercellsbyTcells

TraffickingofCD8+“killer”Tcellstocancertissue4

Releaseoftumorneoantigensandrecruitmentofdendriticcells1

2 Transportofneoantigensbydendriticcellstolymphnodes

PrimingandactivationofCD8+Tcellimmuneresponsetoneoantigens

3 5 InfiltrationofTcellsintocancertissue

ILIXADENCELINJECTION

STEPONTHEGAS:ACTIVATETHEIMMUNESYSTEM

RELEASETHEBRAKE:BLOCKCANCERIMMUNESUPPRESSION

and/orKILLCANCERCELLS

Immunicum’s ilixadencel primesandactivatestheimmunesystemtorecognizeandfindcancercells

Checkpointinhibitors(Keytruda®/Opdivo®)tyrosinekinaseinhibitors(sunitinib)

chemotherapies (gemcitabine)

Ilixadencel:Abackbonetherapyinimmuno-oncologycombinations

88

CurrentpipelineIndication Preclinical PhaseI/II PhaseII PhaseIII

IlixadencelIM-201 Kidney

IlixadencelIM-102 Liver

IlixadencelIM-103 Gastrointestinal

SUBCUVAX/Adenovirusvector TBD

AllogeneicDendriticCellstransfectedwithgenescodingfordesirabletumorantigensImmunicum’sproprietaryadenovectorcanbeusedtodelivergenes,codingforoncoviralantigensorneoantigensandimmune-boostingfactors,intodendriticcells.ThisisthescientificbasisbehindtheSUBCUVAX®approach.However,potentialapplicationsgobeyondthisconcept,byincludinge.g.noveloncolytictreatments.

CD70 TBD

OptimizedCAR-Texpansionprotocolforimprovedanti-canceractivityImmunicum’sCD70platformwasdesignedusingthecompany’scoreexpertiseindendriticcellbiologyandcanprovideCAR-TcompanieswithasuperiortoolforexpansionofCAR-Tcellswithimprovedanti-tumoractivityaswellasahigherresistancetooxidativestressandimmunosuppressivefactorsthattheymustfaceinthetumorenvironment.

99 Source:(1)TransparencyMarketData,KidneyCancerDrugsMarket,2015;(2)GlobalData;(3)MordorIntelligence:GlobalLiverCancerMarket,2016.

C U R R E N T I N D I C AT I O N S

86%

Others

Solidtumors

80%

Others

Solidtumours

Solidtumorsarecausedbynewgrowthoftissueinwhichcellmultiplicationisuncontrolled

andprogressive,formingadiscretetumormasse.g.inthebrain,kidney,

breast,liveretc.

CANCERINCIDENCE

CANCERMORTALITY

Marketoverview:IlixadencelcurrentindicationsAdvancedclinicalstageprojectsinsizeableindicationswithlargeunmetclinicalneeds

GastrointestinalGastrointestinalstromaltumor

(GIST)$1.1bn 2017E2

A D D I T I O N A L P O T E N T I A L

KidneyRenalCellCarcinoma(RCC) $4.5bn 2020E1

LiverHepatocellularCarcinoma

(HCC)$0.7bn20163

1

2

3

4

5

6

Tableofcontents





Financials

Appendix

11

Ilixadencel– Immunicum’sleaddevelopmentcandidateIlixadencel(previouslyINTUVAX)hasthepotentialtobecomepartofstandardtreatmentformostsolidtumors

Uniqueoff-the-shelfproduct– Personalizedtreatmentwithoutcostlyandtimeconsumingper-patientproduction

11

Strongimmunesystemactivation – Recruitmentofcancer-specificTcellstocancersiteandmetastasesfollowinginjection

HighlypromisingPhaseI/IIdata – Morethandoublingofexpectedmedianoverallsurvivaldemonstrated

OngoingPhaseIItrial– International90-patienttrialcomparingcombinationtherapytostandardofcare

Excellentsafetyprofile– Lowrateoftreatment-relatedseriousadverseeventsinthelandscapeofimmunotherapies

Widerangeofapplicability– Ilixadencelisapplicabletomostinjectablesolidtumors

12

Uniquecellbasedoff-the-shelfimmunotherapyproduct

Autologousorexvivo immunotherapypreparationiscostlyandtimeconsuming

Ilixadencelprovidespersonalizedtreatmentdespitebeinganoff-the-shelfproduct

Patientpresentsathospitalfortreatment

Asampleofthecancercellsiscollected

Thesampleissenttoanexternallaboratory

Asinglepersonalizedtherapyisproduced

Thetherapyissentbacktothehospital

Thetherapyisadministered

Patientpresentsathospitalfortreatment

Ilixadencelisadministered

Ilixadencelcomparesfavorablytoexvivotherapiesbyallowingforimmediatetreatmentatlowercost

1XHealthydonorsample

100X DosesofIlixadencel 50X Patients

treated

ILIXADENCELPRODUCTION

ILIXADENCELKEYBENEFITS

ü Ilixadenceltargetsthefullsetofeachpatient’suniqueandtumor-specificmutatedneoantigens.Ilixadencelutilizesthepatient’stumorasaneoantigensourcewithouttheneedtoextractasampleofthecancerforproductionofavaccine,whichisaverycostlyandtimeconsumingprocedure.

ü Ilixadencelutilizeshealthydonorleukapheresis(laboratoryprocedureinwhichwhitebloodcellsareseparatedfromblood)asthesourcematerialusedtomanufacturetheallogeneicdendriticcellproduct(~100dosesfromonehealthydonor).

ü GoodManufacturingPractice(GMP)ataGermancontractmanufacturingorganization.

24MONTHSHELF-LIFE

13

Ilixadencel deliveredpromisingdatainPhaseI/IImRCC trialPatientsreceivingilixadencel showeda3-foldincreasecomparedtohistoricaldata

Time(inmonths)fromstartofilixadencel treatment(asofMay2017)

14.7-15.8monthsexpectedmedianoverallsurvivalinnewlydiagnosedmRCCpatientsonsunitinib(Hengetal.2009;Koetal.2014)

0 10 20 30 40 50 60 70

Stillalive

Startoftyrosine-kinaseinhibitiontreatment

48monthmedianoverallsurvivalaspublishedinJImmunother Cancer(Laurell etal.2017)

14

Casereport:Completeremissionfrom4brainmetastases

Patientwithbrainmetastasesbeforesunitinibtreatment

Showingcompleteresponseof2ofthebrainmetastasessixmonthsafterstartof

sunitinibtreatment

PRIORTOTREATMENT

6MONTHSPOSTTREATMENT

Patienttreatedwithilixadencel showedcompleteremissionfrommetastasesnotaccessiblebysunitinibalone

Patientprofile

• ThepatientwascategorizedaspartofthehighriskgroupaccordingtoMSKCC-criteria

• ThepatientshowedstronginfiltrationofCD8+Tcells (cancerspecificTcellsactivatedbyilixadencel)intheresectedkidneytumor

• Thepatienthaddeveloped4newbrainmetastases,onenewlungmetastasisand5large(upto5cminlargestdiameter)livermetastasesatfollowup3monthsaftertheremovaloftheprimarykidneytumor

• Thepatientreceivedstandardsunitinib(tyrosinekinaseinhibitor)treatmentduetoprogressioninadditiontothepreviouslyreceivedinjectionofilixadencel

• Follow-up3,6and9monthsafterinitiationofsunitinibtreatmentrevealedacontinuoustumorregressionatallmetastaticsites,includingcompleteremissionofallbrainmetastasesandlivermetastases

• Thepatientisstillalive48months(asofMay2017)fromstartofilixadencel

Comments

• Assunitinibhasbeenshowntobeunabletoaffectbraintumors,thecompleteremissionofthesetumorsdemonstratedintheadjacentimagescanbeattributedtoilixadencel inprimingtheimmunesystem,possiblyfurtherfacilitatedbysunitinib’seffectoninhibitingimmunosuppressivecells

Thecasestudysuggestsilixadencel usedincombinationwithcheckpointinhibitorsandotheragentsinhibitingthetumor'simmunosuppressioncouldenableremissionofdistantmetastasesevenwhentheprimarytumor

hasalreadybeenremoved,aswasthecasewiththepatient

15

TumorspecificandsystemicimmuneresponseshownHistopathologicalanalysisofremovedkidneytissueprovidesstrongprooffordesiredimmunereaction

Treatedtumorarea Normalkidneytissuesurroundingtreatedtumorarea MetastasisUntreatedtumorarea(reference)

RENALCELLCARCINOMA

AreferenceslidedemonstratingtheamountofTcells(blackdots)inanon-

treatedtumor.

AmassiveinfiltrationofcancerspecificCD8+Tcellsinthetumorafterinjectionof

ilixadencel.

AclearabsenceofTcellsoutsideofthetumorsite(similartoahealthytissue)

supportingthatthemassiveinfiltrationistumor-specific.

AclearincreasedpresenceofCD8+Tcellsatadistantmetastasis(tumorthathasspreadtootherpartsofthebody)

demonstratesthattheimmunesystemisalsoabletoidentifyandtargetcancercellsinotherpartsofthebodyafter

injectionofilixadencel.

Source:JImmunotherapyCancer.2017;5:52.“Intratumorallyinjectedpro-inflammatoryallogeneicdendriticcellsasimmuneenhancers:afirst-in-humanstudyinunfavorableriskpatientswithmetastaticrenalcellcarcinoma”

TUMOR

16

Updateonongoingclinicaltrialsforilixadencel

GastrointestinalGastrointestinal

stromaltumor(GIST)

RESULTSEXPECTED

2019PhaseI/II:IM-103GISTstudy• Aprospectivesinglearmed,openlabelPhaseI/IIstudybeingcarriedoutin12

patientsattheKarolinskaInstitute• ProtocolamendedinMarch2017tofacilitaterecruitment• Threepatientsenrolledsofar• Trialisplannedtoenrollatotalof12patients

LiverHepatocellularCarcinoma(HCC)

RESULTSEXPECTED

2017• Aprospectivesinglearmed,openlabelPhaseI/IIstudycarriedoutin12patients

withadvancedhepatocellularcarcinomaatSahlgrenskaUniversity• LastpatientrecruitedinNovember2016• Medianoverallsurvivalforsecondlinecohort(7patients)was11.1monthsasof

June2017• Asshowninarecentpublication,theincreaseofthreemonthsinoverallsurvival

overplacebo(10.6monthcomparedto7.8monthinplacebogroup)supportedtheregulatoryapprovalofanovelsecondlinetreatmentandisconsideredasignificantimprovement

PhaseI/II:IM-102HCCstudy

KidneyRenalCellCarcinoma

(RCC)

RESULTSEXPECTED

2019

PhaseII:IM-201mRCCMERECAstudy• MERECAisaninternational,investigational,randomized,controlledandopenstudy

whereatotalof90patientswillreceiveeitherstandardtreatmentofsunitiniborsunitinib withilixadencel

• Totalrecruitmenttodatetotals68patientsat28centersineightEuropeancountriesandtheUS

• FirstpatientrecruitedintheUS• CompletionofenrollmentexpectedinH22017

1

2

3

4

5

6

Tableofcontents





Financials

Appendix

18

Updatedclinicaldevelopmentplan- StrategyAcceleratingvaluecreationandestablishingilixadencelaspartofthestandardofcare

NEWCOMBINATIONSANDINDICATIONS ADVANCEMENTOFCURRENTINDICATIONS PREPARATIONFORPHASEIIITRIALS

HepatocellularCarcinoma(HCC)

PhaseI/II

AdvancementtoPhaseIIbasedonpositivedatafromon-goingPhaseI/IItrial

PhaseII

RenalCellCarcinoma(RCC)

PhaseII

CompletionofMERECAPhaseIIstudytowardspivotalstage

GastrointestinalStromalTumors(GIST)

PhaseI/II

CompletionofGISTPhaseI/IIstudy

PhaseIb/II

Multi-indicationstudycombiningwithcheckpointinhibitors

- Objectivetoestablishthesafetyandtherapeuticimpactforcombinationtherapyinthreenewindicationsforilixadencel

- Thechosenindicationsarewell-suitedforilixadenceltreatmentandrepresentpatientpopulationswithlargeunmetmedicalneeds

- Lessthan50%ofpatientsrespondtocheckpointinhibitors.Illixadencelisuniquelypositionedtoincreasetheefficacyasacombinationtreatment

Manufacturing(CMC)activities

ContinueddevelopmentofChemistry,ManufacturingandControlprocessestoestablishacommercialgrademanufacturingfollowingthe

currentrobustdevelopmentgrademanufacturing

HeadandNeckcancer(SCC)

GastricAdenocarcinoma(GC)

Non-SmallCellLungCancer

300-400m

S E K

Totalcapitalrequirementfor

execution

SEK

71m

athand*

*CashandcashequivalentsplusfundsinvestedinmutualfundsamountedtoSEK70.7masof2017-06-30.

19

Updatedclinicaldevelopmentplan– ValueAdvancedclinicalstageprojectsinsizeableindicationswithlargeunmetclinicalneeds

Source:GLOBOCAN2012;(1)GlobalData,2016;(2)BCCResearch,"GastricCancerTesting,TreatmentandPrevention:TechnologiesandGlobalMarkets,"October,2015; (3)ResearchandMarkets,2017;(4)MordorIntelligence:GlobalLiverCancerMarket,2016;(5)TransparencyMarketData,KidneyCancerDrugsMarket;(6)GlobalData.

NEWCOMBINATIONSANDINDICATIONS

HeadandNeckCancer(HNSCC)

GastricAdenocarcinoma(GC)

Non-SmallCellLungCancer(NSCLC)

ADVANCEMENTOFCURRENTINDICATIONS

HepatocellularCarcinoma(HCC)

RenalCellCarcinoma(RCC)

GastrointestinalStromalTumors(GIST)

• Global:665,000newcases• US:26,000newcases




• Global:1,460,000newcases• US:171,000newcases


$1.5bn2024E1

$3.2bn2020E2

$12.2bn2025E3

Globalmarketsize

Globalmarketsize

Globalmarketsize

$0.7bn20164

$4.5bn2020E5

$1.1bn2017E6

Globalmarketsize

Globalmarketsize

Globalmarketsize

20

Upcomingexpectednewsflow2017-2019N E W S F L O W 2 0 1 7 N E W S F L O W 2 0 1 8 N E W S F L O W 2 0 1 9

PhaseI/II:IM-102HCCtrialtoplineresults

PhaseII:InitiationofIM-203HCCtrialInitiationofCMC feasibilitystudies

PhaseIb/II:Initiationofmulti-indicationstudycombiningilixadencel withcheckpointinhibitors

PhaseII:IM-201RCCMERECAstudytoplineresults

=subjecttofinancing

PhaseI/II:IM-103GISTtrialtoplineresults

PhaseII:IM-201RCCMERECAstudyrecruitmentcompleted

M U L T I P L E I N T E R I M R E A D O U T S , C O L L A B O R A T I O N S A N D P U B L I C A T I O N S A L S O E X P E C T E D D U R I N G T H E P E R I O D

21

Companyhighlights

Favorablepositioningasbackbonetherapyinthefutureoncologytoolkitofcombinationtherapies2

Excellentsafetyprofilewithlowrateoftreatment-relatedseriousadverseevents5

3 Advancedclinicalstageprojectsinsizeableindicationswithlargeunmetneed

6 Robustdevelopmentgrademanufacturinginplace

7 Experiencedmanagementteamwithextensiveexperienceoflatestagedrugandbusinessdevelopment

Uniqueapproachtoimmunesystemactivationthroughanoff-the-shelfproductofferingpersonalizedtreatment1

4 Highlypromisingefficacydataandprovenmechanismofactioninleadcandidate

8 Operatingwithinthefastestgrowingareaforcancertreatment

ThankYou

2323

In brief

Companyfounded 2002

Headquarters Gothenburg

Numberofemployees 10

Totalinvestmenttodate SEK273m

Immunicumisaclinical-stagebiopharmaceuticalcompanyestablishingaunique

immuno-oncologyapproachthroughthedevelopmentofallogeneic,off-the-shelf

cell-basedtherapies.

Thecompany’sgoalistoimprovesurvivaloutcomesandqualityoflifebypriming

thepatient'sownimmunesystemtofightcancer.Thecompany'sleadproduct

ilixadencel,consistingofpro-inflammatoryallogeneicdendriticcells,hasthe

potentialtobecomeabackbonecomponentofmoderncancercombination

treatmentsinavarietyofsolidtumorindications.

FoundedandbasedinSweden,Immunicumispubliclytraded

ontheNasdaqFirstNorthPremier.

TODAY’SPRESENTER

CarlosDeSousaChiefExecutiveOfficer

M.D.,ExecutiveMBA

} JoinedImmunicumasCEOinOctober2016

} Over25yearsofexperiencefromexecutivepositionswithintheglobal

pharmaceuticalandbiotechmarket,includingexperiencefrombusiness

development,acquisitions,globalmarketingandclinicaldevelopment

} MedicalDoctor,SchoolofMedicineatUniversityofLisbonandExecutive

MBA,SternSchoolofBusinessatNewYorkUniversity,born1958

SENIORPOSITIONSHELD

2424

Ilixadencel:Abackbonetherapyinimmuno-oncologycombinations

Killingofcancercells

Afterrecognition,theCD8+Tcellscankillthecancercells,asiffightinganinfection.CancercellscanhoweverdeveloptheabilitytolocallysuppresscancerspecificCD8+Tcellstopreventkilling.Complementingimmunotherapiessuchascheckpointinhibitorscanblockthisability,which“releasesthebrake”ontheimmunesystem.However,ifthereisnoactivatedimmunesystemthat“stepsonthegas”,checkpointinhibitorshavelimitedimpact.Immunotherapycombinations,suchasilixadencel togetherwithcheckpointinhibitors,couldthereforebethesolution.

7

6 Recognitionofcancercells

Afterinfiltration,theCD8+Tcellswillattempttorecognizethecancercellsinordertokillthem.

TraffickingofTcellstocancertissue

ThecancerspecificCD8+Tcellsarereleasedintothebloodtosearchforcancercells.

4

Immunerecruitment

Cancercellsproducespecificsubstancescalledneoantigens.Theseneoantigenscanbeidentifiedbytheimmunesystemasdifferentfromhealthycellsandmaytherebyinduceanimmuneresponse,i.e.recruitthebody’sdefenses.Inordertoinduceastrongresponseasufficientamountofimmunecellshavetoberecruitedtothecancersite.Theroleofilixadencel istotriggertherecruitmentoftheneededcells,i.e.“tosteponthegas”inthecancerimmunitycycle.Ilixadencel isapro-inflammatoryforeignagentthatlocallytriggersanaggressiveimmuneresponse,similartothebody’sresponsetoaviralinfection.Byinjectingilixadencel intothetumor,varioustypesofimmunecellswillberecruitedtotheinjectionsite.Amongtheserecruitedcellsaredendriticcells,whichpickupandtransportneoantigens.

1

2 Transportationtolymphnodes

Thedendriticcellswhichwererecruitedby ilixadencelthentransportthecancerneoantigenstothelymphnodes,wherethebodycreatesdefenses(suchasTcells)tokillthreatsinthebody.

Primingandactivationofimmuneresponsetoneoantigens

Oncethedendriticcellsreachthelymphnodestheythen“present”theneoantigenstoTcellswhichbecomeprimedtowardstherecognized,cancerspecific,neoantigensandbegintoreplicateinordertobuildanattack.ThisresultsinlargeamountsofCD8+Tcells,or“killerTcells”,specificallyactivatedtofindandkillcancercellsintheentirebody.

3

5 InfiltrationintocancertissueTheCD8+Tcellswillinfiltratetheprimarytumorormetastaseselsewhereinthebody.

ILIXADENCELINJECTION

STEPONTHEGAS:ACTIVATETHEIMMUNESYSTEM RELEASETHEBRAKE:BLOCKCANCERIMMUNESUPPRESSION

Ilixadencelplaysanimportantpartinthecancerimmunitycyclebyincreasingtheefficacyofcheckpointinhibitors

Documents

20170913 Immunicum Company Presentationimmunicum.se/wp-content/uploads/2017/09/20170913... · that suppress the immune system’s ability to kill cancer cells through checkpoint